Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/6970
|
| Title: | Front-line antibiotic therapy in early-stage H. Pylori-positive gastric Diffuse Large B-Cell Lymphomas with or without malt features |
| Authors: | Chen, LT;Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Hsu, PN;Wang, HP;Cheng, AL |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Background :Our earlier study showed that certain proportion of early-stage H. pylori (HP)-positive gastric diffuse large B-cell lymphoma (DLBCL) with features of mucosa-associated lymphoid tissue (MALT), DLBCL(MALT), could achieve long-term complete pathological remission (pCR) after frontline HP eradication therapy (HPE). In this retrospective, explorative study, we evaluate the efficacy of HPE on early-stage gastric DLBCL without features of MALT, the pure (de novo) DLBCL, in comparison with its efficacy on high-grade transformed gastric MALT lymphoma, the DLBCL(MALT). Methods :A total of 50 patients of stage IE/IIE1, HP-positive gastric DLBCL with frontline HPE treatment were included. Of them, 16 patients with pure (de novo) DLBCL were retrospectively identified from medical/pathologic review and 34 patients with DLBCL (MALT) were an expanded cohort of one previously reported multicenter prospective study. pCR was defined as regression of DLBCL to Wotherspoon grade 2 or less in all histologic sections of follow-up endoscopic biopsies. Results: HP infection was successfully eradicated in 100% (16/16) of the pure (de novo) DLBCL and 94.1% (32/34) of the DLBCL(MALT) patients. A total of 68.8% (11/16) of pure (de novo) DLBCL and 56.3% (18/32) of DLBCL(MALT) patients achieved pCR after HPE. The median time-to-pCR was 2.1 months (95% CI, 0.6–3.7) for pure (de novo) DLBCL and 5.0 months (95% CI, 2.8–7.5) for DLBCL(MALT) (P = 0.024). At a median follow-up of 7.7 years (95% CI, 4.5–10.9), all patients with pCR after HPE were alive and free of lymphoma, except one patient with pure (de novo) DLBCL died of lung cancer. Conclusions: Similar to DLBCL(MALT), a substantial portion of early-stage, HP-positive gastric pure (de novo) DLBCL remains HP-dependent and responds to antibiotic treatment. Prospective studies to validate the findings are warranted. |
| Date: | 2012-10 |
| Relation: | Annals of Oncology. 2012 Oct;23(Suppl. 11):105. |
| Link to: | http://dx.doi.org/10.1093/annonc/mds572 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000310634300352 |
| Appears in Collections: | [陳立宗] 會議論文/會議摘要
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000310634300352.pdf | | 53Kb | Adobe PDF | 472 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
